Bio Path Company Overview

Bio Path (NASDAQ:BPTH) is a biotech company focused on developing genetic cancer treatments using its proprietary drug delivery platform, DNAbilize®. This innovative technology aims to provide safer, more effective treatment options by specifically targeting cancer cells while sparing healthy ones, primarily focusing on blood cancers and solid tumors. Their portfolio includes promising preclinical and clinical-stage projects aiming to improve patient outcomes and address unmet medical needs in cancer therapy. The company's primary objective is to advance its lead drug candidate, Prexigebersen, through the necessary clinical trials to bring a new generation of cancer treatments to the market.